Hong Kong Regulatory Update – Week of Oct 10‑17, 2026
One new drug approved under the 1+ mechanism for metastatic hormone‑sensitive prostate cancer, bringing total approved drugs to 23; source: info.gov.hk.
Hong Kong’s Pharmacy and Poisons Board and Department of Health announced a new drug approval on 15 October 2026.
Regulatory Updates
- The newly approved drug is indicated for metastatic hormone‑sensitive prostate cancer and was granted registration under the extended “1+” mechanism, which relies on approval from a single reference authority. Source
#PECANSolutions #RegulatoryAffairs #PharmaRegulation #AsiaMarketAccess #HongKong #DrugApproval #PharmacyBoard
Related markets: Hong Kong
Ready to Enter Asian Markets?
PECAN.Solutions is your trusted partner for navigating the complex regulatory landscape of Asian pharmaceutical markets. With our network of local experts and proven track record since 2007, we can help you bring your products to market efficiently and compliantly.
Contact us today to discuss your Asian market entry strategy and learn how we can accelerate your regulatory success.
Contact Us